AEON Biopharma, Inc. (AEON) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00791X2099
AEON Biopharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -12.80 m USD |
| EBIT | -39.22 m USD |
| Net income | -39.22 m USD |
| Diluted EPS – continuing operations | -3.95 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
More stocks
- Vyome Holdings, Inc (HIND)
- Trutankless, Inc. (TKLS)
- SUPA Consolidated Inc. (SFCX)
- MASS MEGAWATTS WIND POWER INC (MMMW)
- RESEARCH FRONTIERS INC (REFR)
- VIP Play, Inc. (VIPZ)
- BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
- STANDARD PREMIUM FINANCE HOLDINGS, INC. (SPFX)
- AVAI BIO, INC. (AVAI)
- Glimpse Group, Inc. (BTLN)
- Wetouch Technology Inc. (WETH)
- Worldwide NFT Inc. (WNFT)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.